CPRX News and Press, Catalyst Pharmaceuticals Inc. From 06/20/23

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Treat Duchenne Muscular Dystrophy Catalyst Exp...

2023-06-01 12:09:13 ET Catalyst Pharmaceuticals ( NASDAQ: CPRX ) reaffirmed its full-year 2023 total revenue and products outlook. The company continues to expect FY23 revenue to be between $375M and $385M, growing 75% to 80% Y/Y (consensus $381.28M). Catalyst also reaffirme...

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Appr...

CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare dise...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-22 08:15:00 ET In the last 30 days, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. As you might be guessing, the culprit for the tumble was the company's abysma...

2023-05-11 11:51:08 ET Catalyst Pharmaceuticals Inc. (CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 am ET Company Participants Patrick McEnany - Chairman, Chief Executive Officer Alicia Grande - Vice President, Chief Financial Officer Jeff Del Carmen -...

2023-05-10 16:38:30 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q1 Non-GAAP EPS of $0.41 beats by $0.10 . Revenue of $85.4M (+98.2% Y/Y) beats by $3.78M . Cash and equivalents were $148.2 Million as of March 31, 2023. Affirms Full Year Tot...

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms F...

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...